Publication: 168

Publication: 168

A Phase II Study Of Estramustine, Docetaxel, And Bevacizumab In Men With Castrate Resistant Prostate Cancer: Results Of Cancer And Leukemia Group B (CALGB) 90006

PubMed

PMC

QxMD

DOI

Google Scholar

Citation:: Cancer vol 117 (3) 526-533

Year:: 2011
Type:: Manuscript
Funding:: NCTN
Endpoint:: Primary
Analysis:: Primary
Data Sharing:: No-Data-Sharing
Status:: Presented/Published
Citation Status:: pmc-release

Note:

Methodological:: No
Biospecimen:: No
SDC:: No
Book Volume:

Parents:: None
Children:: None

Program:: OGC
Primary Committee:: GU
Sec. Committees:

Pharmas:
Grants:: U10 CA032291, CA33601, U10 CA077658, CA77406, CA32291, CA41287, U10 CA035279, U10 CA031946, U10 CA033601, U10 CA045389, CA45389, CA35279, U10 CA045418, U10 CA077440, CA16450, CA77440, U10 CA041287, U10 CA047559, CA47559, CA45418, U10 CA031946-18, CA77658, CA60318, CA77298, CA31946

Corr. Author:
Authors:: Joel Picus Susan Halabi W. Kevin Kelly Nicholas J. Vogelzang Young E. Whang Ellen B. Kaplan Walter M. Stadler Eric J. Small

Networks:

Study: CALGB-90006
Multiple Studies, or Legacy Studies in Alliance Study:
Phases:: 2

Keywords:: Docetaxel, Bevacizumab, castrate resistant prostate cancer